StockNews.com Initiates Coverage on Ayala Pharmaceuticals (NASDAQ:ADXS)

Stock analysts at StockNews.com began coverage on shares of Ayala Pharmaceuticals (NASDAQ:ADXS) in a report released on Sunday. The brokerage set a “sell” rating on the stock.

Ayala Pharmaceuticals Stock Down 69.7 %

Shares of NASDAQ:ADXS opened at $0.03 on Friday. Ayala Pharmaceuticals has a fifty-two week low of $0.00 and a fifty-two week high of $0.78. The firm has a 50-day simple moving average of $0.04 and a 200 day simple moving average of $0.04. The company has a market cap of $1.42 million, a PE ratio of 0.00 and a beta of 1.25.

About Ayala Pharmaceuticals

Ayala Pharmaceuticals, Inc, a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia.